Salubris Biotherapeutics Inc.

2 trials 1 recruiting Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

2 Countries active

4 Unique IMPs

100% Results reported

Phase I (FiH)

Phase I (FiH): 2

Oversight events:

6 temporary halts 1 urgent safety measure across 2 trials

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Clear cell papillary renal cell carcinoma 2 Head and neck cancer 2 Non-small cell lung cancer 2 Endometrial adenocarcinoma 2 Hepatocellular carcinoma 1 Oesophageal squamous cell carcinoma 1 Small cell lung cancer 1 Adenocarcinoma gastric 1 Oesophageal adenocarcinoma 1 Prostate cancer 1 Triple negative breast cancer 1 Breast cancer 1

Top IMPs

JK06 1 JK08 1 LENVATINIB 1 PEMBROLIZUMAB 1

All trials

2 total

A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unre… Recruiting

2024-512421-92-00 Phase I (FiH) 2 countries JK06
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo… Ended

2024-511750-53-00 Phase I (FiH) 2 countries JK08; LENVATINIB; PEMBROLIZUMAB

Showing 1–2 of 2 trials

← All sponsors A–Z